GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (FRA:PF0) » Definitions » DeferredTaxAndRevenue

NetraMark Holdings (FRA:PF0) DeferredTaxAndRevenue : €0.02 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

NetraMark Holdings's current deferred tax and revenue for the quarter that ended in Dec. 2023 was €0.02 Mil.

NetraMark Holdings DeferredTaxAndRevenue Historical Data

The historical data trend for NetraMark Holdings's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings DeferredTaxAndRevenue Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23
DeferredTaxAndRevenue
- - 0.02 0.02

NetraMark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02

NetraMark Holdings DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NetraMark Holdings (FRA:PF0) Business Description

Traded in Other Exchanges
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.

NetraMark Holdings (FRA:PF0) Headlines

No Headlines